A Review on Repurposing Drugs for Treatment of Covid-19

Authors

  • Kamble Sharad Nootan College of Pharmacy. Kavathe Mahankal Dr. Babasaheb Ambedkar Technical University, Lonere http://orcid.org/0000-0002-7713-2947
  • Patil Amol
  • Chikkodi Pramod
  • Navale Sachin
  • Mujawar Alisha

Keywords:

Coronavirus, Repurposing SARS CoV-2, COVID-19, Virus based drugs

Abstract

 

The newly emerged 2019 novel coronavirus is named as severe acute respiratory syndrome 2(SARS CoV-2). Till date, 1,757,393 cases have been observed in India and 37,452 deaths. COVID-19 has been now declared as pandemic and new treatments are urgently needed as we enter a phase beyond containment. In the absence of approved marketed drugs against coronavirus, the treatment and management of novel COVID-19 disease worldwide is a challenge. Developing new drugs from scratch is a lengthy process, and is thus impractical to face the immediate global challenge. Drugs repurposing is an emerging strategy where existing medicines having already been tested safe in humans, are redeployed to combat difficult to treat diseases. The direct virus targeted on antiviral agent target-specific nucleic acid or proteins of the virus or host based antiviral target either the host innate immune response or the cellular machineries that are crucial for viral infections. Both the approaches necessary interfere with the viral pathogenesis. Here, we will summarize the present status of antiviral, antibiotic drugs repurposing perspective for coronavirus in general and the SARS CoV-2 in particular. Some drugs such as ABT 450 which is active agent against hepatitis C, Acyclovir which is active against cytomegalovirus infection and more others such as Amprenavir for HIV, Arbidol for influenza, Brivudin for Herpes Zoster, etc.

 

Keywords: Coronavirus, drug repurposing SARS CoV-2, COVID-19, virus based drugs, ABT 450


Cite this Article

Kamble Sharad, Patil Amol, Chikkodi Pramod, Navale Sachin, Mujawar Alisha. A Review on Repurposing Drugs for Treatment of Covid-19. Research & Reviews: A Journal of Drug Formulation, Development and Production. 2020; 7(3): 16–22p.


Downloads

Published

2021-01-16

Issue

Vol. 7 No. 3 (2020)

Section

Review Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.